頁 1 從 24 結果
FIELD OF THE INVENTION
This invention is directed to the field of medical devices and testing and, more particularly, to apparatus and techniques for evaluating urinary stress incontinence.
BACKGROUND OF THE INVENTION
According to the American Academy of Family Physicians, urinary incontinence (UI)
FIELD OF THE INVENTION
This invention is directed to the field of medical devices and testing and, more particularly, to apparatus and techniques for evaluating urinary stress incontinence.
BACKGROUND OF THE INVENTION
According to the American Academy of Family Physicians, urinary incontinence (UI)
FIELD OF THE INVENTION
This invention is directed to the field of medical devices and testing and, more particularly, to apparatus and techniques for evaluating urinary stress incontinence.
BACKGROUND OF THE INVENTION
According to the American Academy of Family Physicians, urinary incontinence (UI)
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to diarylmethyl piperazine compounds having utility in medical therapy especially as receptor-binding species, e.g., as conjugates in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to diarylmethyl piperazine compounds having utility in medical therapy especially as receptor-binding species, e.g., as conjugates in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to diarylmethyl piperazine compounds having utility in medical therapy especially as receptor-binding species, e.g., as conjugates in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter
TECHNICAL FIELD
The present invention relates generally to a method of modulating substance P by compounds containing calcium sulfate, particularly syngenite, gorgeyite and gypsum, and more specifically, to the synthesis of such compounds as well as their use to treat a variety of conditions
BACKGROUND OF THE INVENTION
The invention relates to antagonists of the neuropeptide neurokinin-1 (NK.sub.1 or NK-1) receptor.
Tachykinins are peptide ligands for neurokinin receptors. Neurokinin receptors, such as NK.sub.1, NK.sub.2 and NK.sub.3, are involved in a variety of biological processes.
BACKGROUND OF THE INVENTION
This invention relates to antagonists of the neuropeptide neurokinin-1 (NK.sub.1 or NK-1) receptor, compositions containing the antagonists, and methods of using the antagonists for the treatment of various diseases and conditions, including emesis, depression, anxiety
FIELD OF THE INVENTION
The present invention relates to novel neurokinin-1 (NK.sub.1 or NK-1) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds, to treat NK.sub.1 receptor mediated diseases and conditions, including, for
FIELD OF THE INVENTION
The present invention relates to novel neurokinin-1 (NK.sub.1 or NK-1) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds, to treat NK.sub.1 receptor mediated diseases and conditions, including, for
FIELD OF THE INVENTION
The present invention relates to novel neurokinin-1 (NK.sub.1 or NK-1) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds, to treat NK.sub.1 receptor mediated diseases and conditions, including, for
FIELD OF THE INVENTION
The present invention relates to novel neurokinin-1 (NK.sub.1 or NK-1) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds, to treat NK.sub.1 receptor mediated diseases and conditions, including, for
FIELD OF THE INVENTION
The present invention relates to novel neurokinin-1 (NK.sub.1 or NK-1) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds, to treat NK.sub.1 receptor mediated diseases and conditions, including, for
FIELD OF THE INVENTION
The present invention relates to novel neurokinin-1 (NK.sub.1 or NK-1) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds, to treat NK.sub.1 receptor mediated diseases and conditions, including, for